Impact of glutathione transferases genes polymorphisms in nevirapine adverse reactions: a possible role for GSTM1 in SJS/TEN susceptibility

Ciccacci, Cinzia; Latini, Andrea; Politi, Cristina; Marazzi, Maria Cristina; Novelli, Giuseppe; Palombi, Leonardo; Borgiani, Paola

doi:10.1007/s00228-017-2295-2

Cited by 14 publications

(16 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was reported that the GSTM1-null and GSTT1-null were associated with the risk of hepatotoxicity in HIV positive patients [17]. In addition, significant association of GSTM1-null with the development of Stevens-Johnson syndrome and toxic epidermal necrolysis has been reported in HIV patients in Mozambique [16]. Therefore, identification of these genes in our antiretroviral-prescribed patients could facilitate the determination of higher-risk groups.…”

Section: Discussionmentioning

confidence: 90%

“…GSTM1, GSTT1 and GSTP1 are located on chromosome 1p13.3; 22q11.2 and 11q13.2 respectively [8,9]. Deletions of GSTM1 and GSTT1 genes as well as the polymorphism c.313A > G (rs1695) in GSTP1 have been associated not only with risk of developing certain multifactorial diseases such as cancer [10], diabetes [11], arterial hypertension [12], inflammatory bowel disease [13], hepatocellular carcinoma [14], but also therapeutic outcomes such as non-small cell lung cancer [15] and AIDS [16,17]. Recently, the G allele of GSTP1 was found to be associated with better performance in Russian athletes [18].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Genetic polymorphism of drug metabolism enzymes (GSTM1, GSTT1 and GSTP1) in the healthy Malian population

et al. 2019

View full text Add to dashboard Cite

Glutathione S-transferase genes, known to be highly polymorphic, are implicated in the process of phase II metabolism of many substrates, including xenobiotics, anticancer and anti-infective drugs. The detoxification activity is linked to individual genetic makeup. Therefore, the identification of alleles and genotypes in these genes within a population may help to better design genetic susceptibility and pharmacogenetic studies. We performed the present study to establish the frequencies of the GSTM1, GSTT1, and GSTP1 c. 313A > G (rs1695) polymorphisms in 206 individuals of the Malian healthy population. GSTM1 and GSTT1 were genotyped by using multiplex polymerase chain reaction, whereas genotypes of GSTP1 were identified by polymerase chain reaction followed by restriction fragment length polymorphism. The frequencies of GSTM1-null and GSTT1-null genotypes were respectively 24.3 and 41.3%. The observed genotype frequencies for GSTP1 were 25.73% homozygous wild-type AA, 49.03% heterozygous AG and 25.24% homozygous mutant GG. The frequency of GSTP1-A allele was 50.24% versus 49.76% for the GSTP1-G allele. The distribution of these three genes was homogeneous between men and women (p > 0.05). We found no statistical association between the presence of a particular profile of GSTM1 or GSTT1 with the genotypes of GSTP1 (p > 0.05). Nevertheless, we noticed that the majority of the individuals harboring the GSTM1-present or the GSTT1-present harbor also the GSTP1-AG genotype. In addition, the triple genotype GSTM1present/GSTT1-present/AG was the most frequent with 25.2%. Our findings will facilitate future studies regarding genetic associations of multifactorial diseases and pharmacogenetic, thus opening the way to personalized medicine in our population.

show abstract

Section: Discussionmentioning

confidence: 90%

Section: Introductionmentioning

confidence: 99%

Genetic polymorphism of drug metabolism enzymes (GSTM1, GSTT1 and GSTP1) in the healthy Malian population

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The search strategy generated 1208 citations, of which 136 appeared to be relevant to the systematic review. Of these 136 studies, 31 were excluded, leaving 105 studies eligible for the systematic review (Figure and Table ). Among the 105 studies (5554 cases and 123 548 controls) included in the systematic review on genetic predictors potentially associated with T cell–mediated hypersensitivity to drugs, 52 were related to carbamazepine (CBZ) (n = 31) (Table ) or other aromatic antiepileptic drugs (n = 24, three studies also addressed CBZ) (Table ) .…”

Section: Resultsmentioning

confidence: 99%

Genetic variants associated with T cell–mediated cutaneous adverse drug reactions: A PRISMA‐compliant systematic review—An EAACI position paper

Oussalah

Yip

Mayorga

et al. 2020

Allergy

View full text Add to dashboard Cite

Abderrahim Oussalah and Vincent Yip First authors share an equal contribution.Jean-Louis Guéant and Munir Pirmohamed Senior authors share an equal contribution. AbstractDrug hypersensitivity reactions (DHRs) are associated with high global morbidity and mortality. Cutaneous T cell-mediated reactions classically occur more than 6 hours after drug administration and include life-threatening conditions such as toxic epidermal necrolysis, Stevens-Johnson syndrome, and hypersensitivity syndrome. Over the last 20 years, significant advances have been made in our understanding of the pathogenesis of DHRs with the identification of human leukocyte antigens as predisposing factors. This has led to the development of pharmacogenetic screening tests, such as HLA-B*57:01 in abacavir therapy, which has successfully reduced the incidence of abacavir hypersensitivity reactions. We have completed a PRISMAcompliant systematic review to identify genetic associations that have been reported in DHRs. In total, 105 studies (5554 cases and 123 548 controls) have been included in the review reporting genetic associations with carbamazepine (n = 31), other aromatic antiepileptic drugs (n = 24), abacavir (n = 11), nevirapine (n = 14), trimethoprim-sulfamethoxazole (n = 11), dapsone (n = 4), allopurinol (n = 10), and other drugs (n = 5). The most commonly reported genetic variants associated with DHRs are located in human leukocyte antigen genes and genes involved in drug metabolism pathways. Increasing our understanding of genetic variants that contribute to DHRs will allow us to improve diagnosis, develop new treatments, and predict and prevent DHRs in the future. K E Y W O R D Scutaneous adverse drug reactions, genetic variants, human leukocyte antigen genes, systematic review, T cell-mediated drug hypersensitivity reactions | 1071 OUSSALAH et AL. | MATERIAL S AND ME THODS | Electronic search queryThe literature search was conducted using MEDLINE ® -indexed literature using the PubMed search engine from the National Center for Biotechnology Information (www.pubmed.gov) (January 1966 to April 2019), Embase ® , and ISI Web of Knowledge using the full electronic search strategies detailed in the Appendix S1. Additional articles were retrieved from primary search references. The present systematic review was performed in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement. 12 | Eligibility criteriaA study was considered eligible for the systematic review if it had investigated the association between any genetic variant and any T cell-mediated hypersensitivity reaction to drugs affecting the skin.Both candidate gene and genome-wide association study (GWAS) approaches were eligible for the systematic review. The exclusion criteria were as follows: non-English-language publication; meeting abstracts; case reports; review papers; comparison or assessment of genotyping methods; experimental mechanistic studies; no genetic association study between any genetic variant and any T cell-media...

show abstract

“…Singh et al, (2017) showed that GSTT1-null and GSTM1-null genotypes alone and in combination may predict the acquisition of hepatotoxicity, so disease progression [36]. Ciccacci et al, (2017) shown that only GSTM1-null was associated to HIV disease progression [37]. Kuleape et al, (2018) found that double deletion of glutathione S-transferase M1 and T1 is statistically associated with normal CD4+ count in Ghanaians patients diagnosed with HIV/ AIDS [38].…”

Section: Discussionmentioning

confidence: 99%

Role of Glutathione S-Transferase (<i>GSTM</i>1 and <i>GSTT</i>1) Genes Deletion in Susceptibility to HIV-1 Disease Progression

Djigma¹,

Sorgho²,

Soubeïga³

et al. 2020

JBM

View full text Add to dashboard Cite

Background: Glutathione S-transferases (GSTs) are multifunctional enzymes which play an important role in oxidative stress pathways by conjugation with glutathione. Oxidative stress is one of several risk factors that may be associated with many types of diseases progression such as cancer and infectious diseases. In this study, we investigated the association between the polymorphism of GSTM1 and GSTT1 genes and the risk of HIV-1 disease progression. Methods: We conducted a case-control study including 313 participants of Burkina Faso: 153 HIV-1 infected individuals on antiretroviral treatment (ART) and 160 HIV-1 negative individuals as controls. Presence or absence of the GSTM1 and GSTT1 genes was determined using multiplex polymerase chain reaction (PCR). CD4 + T counts and HIV-1 viral load were measured in patients using respectively BD FACSCount and Abbott m2000rt instruments. Results: Frequencies of GSTM1-null and GSTT1-null were 30.35% and 35.46% respectively and the frequency of double deletion GSTM1-null/GSTT1-null was 14.38% in the general study population. GSTM1-null (30.35% versus 69.65%; OR = 1.90; p = 0.010), GSTT1-null (35.46% versus 64.54%; OR = 3.11; p < 0.001), GSTM1-active/GSTT1-null (21.08% versus 48.56%; OR = 3.17; p < 0.001) and the double deletion GSTM1-null/GSTT1-null (14.38% versus 48.56%; OR = 4.46; p < 0.001) were more present in cases group than controls and differences

show abstract

Impact of glutathione transferases genes polymorphisms in nevirapine adverse reactions: a possible role for GSTM1 in SJS/TEN susceptibility

Abstract: We observed an association between GSTM1 and SJS/TEN susceptibility. Moreover, GSTM1 contributes to the definition of a genetic risk profile for SJS/TEN susceptibility.

Cited by 14 publications

References 40 publications

Genetic polymorphism of drug metabolism enzymes (GSTM1, GSTT1 and GSTP1) in the healthy Malian population

Genetic polymorphism of drug metabolism enzymes (GSTM1, GSTT1 and GSTP1) in the healthy Malian population

Genetic variants associated with T cell–mediated cutaneous adverse drug reactions: A PRISMA‐compliant systematic review—An EAACI position paper

Role of Glutathione S-Transferase (<i>GSTM</i>1 and <i>GSTT</i>1) Genes Deletion in Susceptibility to HIV-1 Disease Progression

Contact Info

Product

Resources

About

Impact of glutathione transferases genes polymorphisms in nevirapine adverse reactions: a possible role for GSTM1 in SJS/TEN susceptibility

Abstract: We observed an association between GSTM1 and SJS/TEN susceptibility. Moreover, GSTM1 contributes to the definition of a genetic risk profile for SJS/TEN susceptibility.

Cited by 14 publications

References 40 publications

Genetic polymorphism of drug metabolism enzymes (GSTM1, GSTT1 and GSTP1) in the healthy Malian population

Genetic polymorphism of drug metabolism enzymes (GSTM1, GSTT1 and GSTP1) in the healthy Malian population

Genetic variants associated with T cell–mediated cutaneous adverse drug reactions: A PRISMA‐compliant systematic review—An EAACI position paper

Role of Glutathione S-Transferase (&lt;i&gt;GSTM&lt;/i&gt;1 and &lt;i&gt;GSTT&lt;/i&gt;1) Genes Deletion in Susceptibility to HIV-1 Disease Progression

Contact Info

Product

Resources

About

Role of Glutathione S-Transferase (<i>GSTM</i>1 and <i>GSTT</i>1) Genes Deletion in Susceptibility to HIV-1 Disease Progression